中轴型银屑病关节炎表型差异与治疗持续性:多中心大队列研究
该回顾性多中心队列纳入621例中轴型银屑病关节炎(PsA)患者,分为孤立型、寡关节型及多关节型三种表型,比较临床特征并评估一线b/tsDMARDs治疗持续性。结果显示多关节型HLA-B27阳性率及骶髂关节炎频率较低而脊柱炎更常见,治疗持续性在寡关节型最长、多关节型最短,且疼痛与HLA-B27状态与停药风险独立相关。
要点
- 中轴型PsA可分为孤立型、寡关节型与多关节型,三型临床特征存在差异。
- 寡关节型一线b/tsDMARDs治疗持续性最长(62个月),多关节型最短(38个月)。
- VAS整体疼痛较高与停药风险增加相关,HLA-B27阳性与治疗持续性延长相关。
核心结论
- 中轴型PsA的治疗持续性因临床表型、HLA-B27状态和疼痛而异,支持临床实践中进行表型分层。
研究设计与样本
- 回顾性多中心队列研究,纳入621例中轴型PsA患者,按孤立型、寡关节型、多关节型分组,采集基线人口学、临床、治疗、实验室及影像学数据。
- 采用Kaplan-Meier分析评估治疗持续性,LASSO Cox回归识别与停药相关的基线因素。
主要发现
- 621例中孤立型占28.2%(175例),寡关节型占40.6%(252例),多关节型占31.2%(194例)。
- 银屑病在孤立型(82.3%)和寡关节型(82.1%)中比多关节型(66.1%)更常见(P < 0.001)。
- HLA-B27阳性率在多关节型为10.9%,低于孤立型的18.9%和寡关节型的21.6%(P = 0.02)。
- 骶髂关节炎在孤立型(70.3%)和寡关节型(65.7%)中比多关节型(53.6%)更常见(P < 0.001),而脊柱炎在多关节型更常见(15.0% vs 寡关节型8.3%和孤立型6.3%;P < 0.001)。
- 治疗持续性在寡关节型最长(62个月,95% CI 43-67),多关节型最短(38个月,95% CI 24-49)(P = 0.006)。
关键数值与推荐
- VAS整体疼痛较高与治疗持续性缩短相关(aHR 1.010,95% CI 1.003-1.018,P = 0.009)。
- HLA-B27阳性与治疗持续性延长相关(aHR 0.56,95% CI 0.32-0.99,P = 0.045)。
临床怎么用
- 临床可根据中轴型PsA的表型(孤立型、寡关节型、多关节型)预判治疗持续性差异。
- 对VAS整体疼痛较高的患者需关注早期停药风险,HLA-B27阳性者治疗持续性可能更长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare clinical features across three axial psoriatic arthritis (PsA) phenotypes: (i) isolated axial PsA, (ii) axial PsA with oligoarticular involvement (axial PsA+oligo), and (iii) axial PsA with polyarticular disease (axial PsA+poly), and assess persistence of first-line biologic and targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs). METHODS: Baseline demographic, clinical, therapeutic, laboratory, and imaging data were retrospectively collected. Kaplan-Meier analysis evaluated treatment persistence, and LASSO Cox regression identified baseline factors associated with discontinuation. RESULTS: Among 621 patients, 175 (28.2%) had isolated axial PsA, 252 (40.6%) axial PsA+oligo, and 194 (31.2%) axial PsA+poly. Psoriasis was more frequent in isolated axial PsA and axial PsA+oligo than in axial PsA+poly (82.3% and 82.1% vs 66.1%; P < 0.001), with lower Human Leukocyte Antigens (HLA)-B27 positivity in axial PsA+poly (10.9% vs 18.9% in isolated axial PsA and 21.6% in axial PsA+oligo; P = 0.02). Sacroiliitis was more frequent in isolated axial PsA (70.3%) and axial PsA+oligo (65.7%) than in axial PsA+poly (53.6%, P < 0.001), whereas spondylitis was more frequent in axial PsA+poly (15.0% vs 8.3% in axial PsA+oligo and 6.3% in isolated axial PsA; P < 0.001). Treatment persistence was longest in axial PsA+oligo (62 months, 95% CI 43-67) and shortest in axial PsA+poly (38 months, 95% CI 24-49) (P = 0.006). Higher VAS global pain was associated with shorter persistence (aHR 1.010, 95% CI 1.003-1.018, P = 0.009), whereas HLA-B27 positivity (aHR 0.56, 95% CI 0.32-0.99, P = 0.045) with longer persistence. CONCLUSION: Treatment persistence in axial PsA varies according to clinical phenotypes, HLA-B27 status and pain, supporting the relevance of phenotypic stratification in clinical practice.
引用
- Lopalco G, Del Vescovo S, Luchetti MM, et al. Phenotypic differences and treatment persistence in a large multicentre cohort of axial psoriatic arthritis. Rheumatology (Oxford). 2026. PMID: 41999231. doi:10.1093/rheumatology/keag209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。